Centene (NYSE:CNC) reaffirmed its 2026 adjusted diluted earnings-per-share guidance of more than $4.80 at the Deutsche Bank Healthcare Summit, with Chief Executive Officer Sarah London saying the company’s performance through the first two months of the third quarter was in line with expectations.
Royal Bank Of Canada (NYSE:RY) Chief Financial Officer Katherine Gibson said the bank has made progress toward the strategic and financial objectives outlined at its Investor Day, citing growth across Canadian and global businesses, improved profitability and cost discipline.
Speaking at a Barclays
Rockwell Automation (NYSE:ROK) executives said customer sentiment remains broadly positive despite inflation, tariffs and trade-policy uncertainty, with manufacturers continuing to prioritize productivity, modernization and automation investments.
Speaking at Morgan Stanley’s 14th Annual Laguna Con
Troim purchased shares indirectly through Drew Trust at $4.38 each, signaling confidence in the offshore drilling company following a strong 43% one-year return.
Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.
Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t
Nvidia's 55.6% net margin dwarfs Applied Materials' 24.7%, but one trades at a steep valuation premium while the other faces customer concentration risk.
Turn Your Earpiece Time Into Actual CashMobile phones have evolved far beyond simple communication gimmick or tool for social sensitive scrolling. Today, s
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk.
Duri
Brookfield Asset Management (NYSE:BAM) used its 2026 Investor Day to outline plans to double fee-bearing capital by 2031, supported by fundraising across flagship funds, complementary strategies, insurance capital and private wealth products. Management also emphasized the July acquisition of the re
Comparing this relatively small part of Berkshire's business to its publicly traded counterparts illustrates just how enormous the conglomerate has become.
Definium Therapeutics (NASDAQ:DFTX) reported positive top-line results from Panorama, its second Phase III study of DT120 ODT 100 mcgs in generalized anxiety disorder, or GAD. The company said the single-dose treatment met its primary endpoint and all key secondary endpoints, adding to positive pivo
Turn Your Phone Time Into Real CashMobile earpiece experience evolved far beyond simple communication devices or tools for social media scrolling. Today, s
